For citations:
Tsimafeyeu I.V., Sultanbaev A.V., Dubovichenko D.M., Murzalina M.J., Volkov A.A., Orlova R.V., Utyashev I.A., Malina G.D., Gluzman M.I. Real-world outcomes of lenvatinib plus pembrolizumab in intermediateand poor-risk metastatic renal cell carcinoma. Cancer Urology. 2025;21(2):42-47. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-2-42-47
Email this article 